Recent Updates
Recently added Catalysts

CTX460

Phase 1/2

Alpha-1 Antitrypsin Deficiency (AATD) | Small Molecules | Other |CRISPR Therapeutics AG|Trials Updated: Nov 13, 2026

CTX460 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Sep 2026

CTX460 target and mechanism

Molecular targetSERPINA1
ModalitySmall Molecules

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDDMC
Total Trials1
Total Enrollment68

FDA Designations

No designations recorded

CTX460 clinical trials

CTX460 · 1 trial · 1 indication

Phase 1/2 1
NCT07850076A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)Alpha-1 Antitrypsin Deficiency (AATD)
RECRUITING68 Analytics
PHASE1/PHASE2RECRUITING
A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)
Alpha-1 Antitrypsin Deficiency (AATD)Unlock trial analytics

Study Endpoints

Primary Endpoints

Phase 1: To evaluate the safety and tolerability of CTX460 in adults with emphysema associated with severe AATD and to determine the recommended Phase 2 dose(s)
From CTX460 infusion up to 36 months

Incidence of DLTs and frequency of AEs

Phase 2: To assess the efficacy of CTX460 in adults with severe AATD and emphysema
6 months from CTX460 infusion

Absolute blood levels of total AAT at Month 6

Secondary Endpoints

Phase 1: To assess the preliminary efficacy of CTX460
6 months from CTX460 infusion
Phase 2: To further characterize the safety of CTX460
From CTX460 infusion up to 36 months
Phase 1/2: To assess the efficacy of CTX460
From CTX460 infusion up to 36 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Phase 1EXPERIMENTALPhase 1 begins with dose escalation based on a single infusion of CTX460.
Phase 2EXPERIMENTALRecommended Phase 2 dose of CTX460.

Interventions

NameTypeDescription
CTX460DRUGCTX460 is a lipid nanoparticle (LNP) formulation of synthetic nucleotide template polymerase (SyNTase) editor for in vivo gene editing of the serine protease inhibitor A1 (SERPINA1) gene in adults with emphysema associated with severe alpha-1 antitrypsin deficiency (AATD).
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Age: ≥18 and ≤75 years. 2. Able to provide written informed consent. 3. Diagnosis of AATD with PiZZ homozygous genotype. 4. Serum total AAT level \<11µM in the absence of augmentation. 5. Emphysema on a CT scan at screening. 6. A postbronchodilator forced expiratory volume in...

Countries:Australia
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 13, 2026NCT07850076Status: NOT_YET_RECRUITING → RECRUITING
LOWNov 13, 2026NCT07850076Status: NOT_YET_RECRUITING → RECRUITING
LOWSep 30, 2026NCT07850076NEW_TRIAL: changed
LOWSep 30, 2026NCT07850076NEW_TRIAL: changed

Frequently asked questions about CTX460

What is CTX460?

CTX460 is an investigational small molecule developed by CRISPR Therapeutics AG for alpha-1 antitrypsin deficiency (AATD), a genetic condition that can lead to emphysema. It is being studied in adults with emphysema associated with severe AATD and is currently in Phase 1/2 clinical development.

What does CTX460 target?

CTX460 targets SERPINA1, the gene that encodes alpha-1 antitrypsin. By acting on SERPINA1, the small molecule is designed to address the underlying deficiency in AATD. The Phase 1/2 trial evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CTX460 in adults with emphysema associated with severe AATD.

Who makes CTX460?

CTX460 is being developed by CRISPR Therapeutics AG, which trades under the ticker CRSP. The company is running the clinical program for CTX460 in alpha-1 antitrypsin deficiency, with the compound currently in Phase 1/2 development.

What phase is CTX460 in?

CTX460 is in Phase 1/2 clinical development. It is investigational and is being studied in a single recruiting Phase 1/Phase 2 trial in adults with emphysema associated with severe alpha-1 antitrypsin deficiency. The study has an estimated enrollment of 68 participants.

What clinical trials is CTX460 in?

CTX460 is being studied in trial NCT07850076, titled a trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CTX460 in adults with emphysema associated with severe alpha-1 antitrypsin deficiency. The Phase 1/Phase 2 study is recruiting, is controlled, enrolls an estimated 68 participants, and is conducted in Australia.

What is CTX460 used for in alpha-1 antitrypsin deficiency?

CTX460 is being developed for alpha-1 antitrypsin deficiency (AATD), specifically for adults with emphysema associated with severe AATD. The Phase 1/2 trial enrolls participants aged 18 years and older of all sexes and assesses safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of the small molecule.